|
1
|
Schulert GS, Minoia F, Bohnsack J, Cron
RQ, Hashad S, KonÉ-Paut I, Kostik M, Lovell D, Maritsi D, Nigrovic
PA, et al: Effect of biologic therapy on clinical and laboratory
features of macrophage activation syndrome associated with systemic
juvenile idiopathic arthritis. Arthritis Care Res (Hoboken).
70:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cimaz R: Systemic-onset juvenile
idiopathic arthritis. Autoimmun Rev. 15:931–934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kawai S and Yamamoto K: Safety of
tacrolimus, an immunosuppressive agent, in the treatment of
rheumatoid arthritis in elderly patients. Rheumatology (Oxford).
45:441–444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo H, Abe T, Hashimoto H, Uchida S,
Irimajiri S, Hara M and Sugawara S: Efficacy and safety of
tacrolimus (FK506) in treatment of rheumatoid arthritis: A
randomized, double blind, placebo controlled dose-finding study. J
Rheumatol. 31:243–251. 2004.PubMed/NCBI
|
|
5
|
Chandrasekhara PK, Jayachandran NV, Thomas
J, Agrawal S and Narsimulu G: Successful treatment of pyoderma
gangrenosum associated with juvenile idiopathic arthritis with a
combination of topical tacrolimus and oral prednisolone. Clin
Rheumatol. 28:489–490. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y,
Inoue N and Yachie A: Treatment of refractory polyarticular
juvenile idiopathic arthritis with tacrolimus. Rheumatology
(Oxford). 53:2120–2122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka H, Tsugawa K, Suzuki K, Oki ES,
Nonaka K, Kimura S and Ito E: Treatment of difficult cases of
systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J
Pediatr. 166:1053–1055. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang D, Chen X and Li Z: Treatment of
patients with systemic-onset juvenile idiopathic arthritis with
tacrolimus. Exp Ther Med. 17:2305–2309. 2019.PubMed/NCBI
|
|
9
|
Jusko WJ, Thomson AW, Fung J, McMaster P,
Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE,
Lieberman R, et al: Consensus document: Therapeutic monitoring of
tacrolimus (FK-506). Ther Drug Monit. 17:606–614. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Venkataramanan R, Swaminathan A, Prasad T,
Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G and
Starzl T: Clinical pharmacokinetics of tacrolimus. Clin
Pharmacokinet. 29:404–430. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vadcharavivad S, Praisuwan S,
Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population
pharmacokinetics of tacrolimus in Thai kidney transplant patients:
Comparison with similar data from other populations. J Clin Pharm
Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Monchaud C, de Winter BC, Knoop C, Estenne
M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R,
Marquet P and Rousseau A: Population pharmacokinetic modelling and
design of a Bayesian estimator for therapeutic drug monitoring of
tacrolimus in lung transplantation. Clin Pharmacokinet. 51:175–186.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wallin JE, Friberg LE, Fasth A and Staatz
CE: Population pharmacokinetics of tacrolimus in pediatric
hematopoietic stem cell transplant recipients: New initial dosage
suggestions and a model-based dosage adjustment tool. Ther Drug
Monit. 31:457–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y
and Li G: Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A
polymorphism on pharmacokinetics of Tacrolimus in Chinese adult
liver transplant patients. Xenobiotica. 45:840–846. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y,
Sun XY, Rao W, Qu W, Li WZ and Sun LY: Population pharmacokinetic
analysis of tacrolimus early after Chinese pediatric liver
transplantation. Int J Clin Pharmacol Ther. 53:75–83. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Musuamba FT, Guy-Viterbo V, Reding R,
Verbeeck RK and Wallemacq P: Population pharmacokinetic analysis of
tacrolimus early after pediatric liver transplantation. Ther Drug
Monit. 36:54–61. 2014.PubMed/NCBI
|
|
17
|
Lu YX, Su QH, Wu KH, Ren YP, Li L, Zhou TY
and Lu W: A population pharmacokinetic study of tacrolimus in
healthy Chinese volunteers and liver transplant patients. Acta
Pharmacol Sin. 36:281–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andreu F, Colom H, Grinyó JM, Torras J,
Cruzado JM and Lloberas N: Development of a population PK model of
tacrolimus for adaptive dosage control in stable kidney transplant
patients. Ther Drug Monit. 37:246–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergmann TK, Hennig S, Barraclough KA,
Isbel NM and Staatz CE: Population pharmacokinetics of tacrolimus
in adult kidney transplant patients: Impact of CYP3A5 genotype on
starting dose. Ther Drug Monit. 36:62–70. 2014.PubMed/NCBI
|
|
20
|
Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J,
Lee JI, Oh JM and Kim IW: Population
pharmacokinetic-pharmacogenetic model of tacrolimus in the early
period after kidney transplantation. Basic Clin Pharmacol Toxicol.
114:400–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang DD, Chen X and Li ZP: Wuzhi capsule
and haemoglobin influence tacrolimus elimination in paediatric
kidney transplantation patients in a population pharmacokinetics
analysis: A retrospective study. J Clin Pharm Ther. 44:611–617.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang D, Chen X, Xu H and Li Z: Population
pharmacokinetics and dosing regimen optimization of tacrolimus in
Chinese pediatric hematopoietic stem cell transplantation patients.
Xenobiotica. Apr 2;1–8. 2019.doi: 10.1080/00498254.2019.1601791
(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Wang DD, Chen X, Fu M, Zheng QS, Xu H and
Li ZP: Model extrapolation to a real-world dataset: Evaluation of
tacrolimus population pharmacokinetics and drug interaction in
pediatric liver transplantation patients. Xenobiotica. Jul 3;1–9.
2019.doi: 10.1080/00498254.2019.1631505 (Epub ahead of print).
View Article : Google Scholar
|
|
24
|
Wang D, Lu J, Li Q and Li Z: Population
pharmacokinetics of tacrolimus in pediatric refractory nephrotic
syndrome and a summary of other pediatric disease models. Exp Ther
Med. 17:4023–4031. 2019.PubMed/NCBI
|
|
25
|
Anderson BJ and Holford NH:
Mechanism-based concepts of size and maturity in pharmacokinetics.
Annu Rev Pharmacol Toxicol. 48:303–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang DD, Ye QF, Chen X, Xu H and Li ZP:
Population pharmacokinetics and initial dosing regimen optimization
of cyclosporin in pediatric hemophagocytic lymphohistiocytosis
patients. Xenobiotica. Aug 14;1–7. 2019.doi:
10.1080/00498254.2019.1651419 (Epub ahead of print). View Article : Google Scholar
|
|
27
|
Wang D, Chen X and Li Z: Population
pharmacokinetics of sirolimus in pediatric patients with kaposiform
hemangioendothelioma: A retrospective study. Oncol Lett.
18:2412–2419. 2019.PubMed/NCBI
|
|
28
|
Sprandel KA, Drusano GL, Hecht DW,
Rotschafer JC, Danziger LH and Rodvold KA: Population
pharmacokinetic modeling and Monte Carlo simulation of varying
doses of intravenous metronidazole. Diagn Microbiol Infect Dis.
55:303–309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hahn D, Hodson EM, Willis NS and Craig JC:
Corticosteroid therapy for nephrotic syndrome in children. Cochrane
Database Syst Rev. CD0015332015.PubMed/NCBI
|
|
30
|
Tanaka H, Tsugawa K, Nakahata T, Suzuki K
and Ito E: Leukocytapheresis for the treatment of refractory
systemic-onset juvenile idiopathic arthritis. Clin Rheumatol.
26:1014–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kimura Y, Pinho P, Walco G, Higgins G,
Hummell D, Szer I, Henrickson M, Watcher S and Reiff A: Etanercept
treatment in patients with refractory systemic onset juvenile
rheumatoid arthritis. J Rheumatol. 32:935–942. 2005.PubMed/NCBI
|
|
32
|
Quartier P, Taupin P, Bourdeaut F, Lemelle
I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S,
LeBideau M, et al: Efficacy of etanercept for the treatment of
juvenile idiopathic arthritis according to the onset type.
Arthritis Rheum. 48:1093–1101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mok CC, Tong KH, To CH, Siu YP and Au TC:
Tacrolimus for induction therapy of diffuse proliferative lupus
nephritis: An open-labeled pilot study. Kidney Int. 68:813–817.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kauffman RE and Kearns GL: Pharmacokinetic
studies in paediatric patients. Clinical and ethical
considerations. Clin Pharmacokinet. 23:10–29. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anderson BJ and Holford NH: Tips and traps
analyzing pediatric PK data. Paediatr Anaesth. 21:222–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holford NH: A size standard for
pharmacokinetics. Clin Pharmacokinet. 30:329–332. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Savage VM, Deeds EJ and Fontana W: Sizing
up allometric scaling theory. PLoS Comput Biol. 4:e10001712008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jacobo-Cabral CO, García-Roca P,
Romero-Tejeda EM, Reyes H, Medeiros M, Castañeda-Hernández G and
Trocóniz IF: Population pharmacokinetic analysis of tacrolimus in
Mexican paediatric renal transplant patients: Role of CYP3A5
genotype and formulation. Br J Clin Pharmacol. 80:630–641. 2015.
View Article : Google Scholar : PubMed/NCBI
|
